FIELD: medicine.
SUBSTANCE: invention refers to medicine and concerns a method of treating and preventing HIV infection of type 1 subtype A (HIV-1A), in which HIV-1A genome structure is extracted from infected patient, primary structure of 14 N-terminal amino acids of Tat-protein in extracted HIV-1A genome is determined, personalized drug is created in the form of 6-peptidyl substituted with aminopenicillanic acid derivatives (6-peptidil - APA) peptide, having amino acid sequence, coinciding with the first 14 N-terminal amino acids of Tat-protein in extracted HIV-1A genome of infected patient, and obtained personalized preparation is administrated to patient.
EFFECT: invention provides effective treatment and prevention of HIV-1A, minimized side effect of vaccination process.
3 cl, 9 ex, 7 dwg, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC AGENT FOR TREATING VIRAL HEPATITIS C | 2014 |
|
RU2568872C1 |
| CODING DNA (cDNA) FOR MAKING VIRUS-LIKE PARTICLES OF HEPATITIS C VIRUS, METHOD FOR MAKING VIRUS-LIKE PARTICLES AND BASED PHARMACEUTICAL COMPOSITION | 2007 |
|
RU2375449C2 |
| IMMUNOGENIC COMPOSITION CONTAINING SYNTHETIC PEPTIDES REPEATING SEQUENCE OF V3-LOOP OF SHELL PROTEIN GP120 HIV1 | 2017 |
|
RU2694576C2 |
| IMMUNOPROPHYLACTIC VACCINE AGAINST HIV BASED ON HIV-SPECIFIC ANTIBODIES | 2008 |
|
RU2505604C2 |
| EXOSOMES-ONKOSOM PREPARATION AND METHOD FOR IMMUNOTHERAPY OF SOLID TUMOURS USING THEREOF | 2014 |
|
RU2593003C2 |
| pBMC-gp140(A)-hum EXPRESSION PLASMA DNA | 2006 |
|
RU2346044C2 |
| NEW Tat-COMPLEXES AND VACCINES CONTAINING THEM | 2005 |
|
RU2432356C2 |
| METHODS AND COMPOSITION FOR INHIBITION OF HIV-1 MULTIPLICATION | 2001 |
|
RU2275379C2 |
| VACCINE AGAINST HIV/AIDS | 2010 |
|
RU2475264C2 |
| OLIGOMERIC PARTICLE INDUCING IMMUNITY AGAINST HEPATITIS C VIRUS, METHOD FOR PREPARING OLIGOMERIC PARTICLE, COMPOSITION, SPECIFIC ANTIBODY, SET (VARIANTS), IMMUNOLOGICAL ANALYSIS AND VACCINE AGAINST HEPATITIS C VIRUS | 1999 |
|
RU2247729C2 |
